United States · 
What does Clarus Ventures invest in?
Clarus Ventures invests most often at Series B and Series A (49% of the rounds on record), in sectors such as AI & Machine Learning, Broadcasting and Community.
Clarus Ventures highlights
- 01
4 cheques in the last 12 months
- 02
Mostly Series B and Series A: 49% of its rounds
- 03
Sole investor in 6 rounds, median $18M
- 04
10 exits from the portfolio
What they do
Filed 2 private fund offerings with the SEC, the most recent in 2025-10From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- GrowthPre-seedSeedSeries ASeries B
- Sectors
- AI & Machine LearningBroadcastingCommunity
- Based in
- Cambridge, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first73 appearances
- 2026
4 rounds
- Oct
- Oct
- Jul
- May
- 2021
1 round
- Jul
- 2019
1 round
- Nov
- 2018
1 round
- Jun
- 2017
2 rounds
- Sept
- Feb
- 2016
2 rounds
- Aug
- Jun
- 2015
1 round
- Oct
- 2014
4 rounds
- Dec
- Nov
- Nov
- Oct
- 2013
8 rounds
- Nov
- Jun
- May
- Apr
- Apr
- Feb
- Jan
- Jan
- 2012
8 rounds
- Dec
- Nov
- Oct
- Oct
- Jul
- Jun
- Apr
- Mar
- 2011
6 rounds
- Dec
- Nov
- Oct
- Aug
- Jul
- Mar
- 2010
11 rounds
- Dec
- Sept
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration24 named
AAA.J. AgarwalSenior Managing Director of the General Partner of the GPiFiling they signed
AMA.J. MurphyOfficer of the General Partner of the Special General PartneriFiling they signed
AMAgne MillerDIRECTORiFiling they signed
ALAlex LeonardDirector of the ManageriFiling they signed
ANAlicia NovakOfficer of the General Partner of the Special GPiFiling they signed
ASAllie SweeneySenior Managing Director of the General Partner of the GPiFiling they signed
AZAmanda ZieglerManaging Director of the General Partner of the GPiFiling they signed
AGAna Gonzalez-IglesiasManaging Director of the General Partner of the Special GPiFiling they signed
AJAndre J. FernandezDirectoriFiling they signed
AWAnthony W. BeovichManaging Director of the General Partner of the Special GPiFiling they signed
AFAnthony F. Marone, JrManaging Director of the General Partner of the GPiFiling they signed
AFAnthony F. Marone, Jr.Managing Director of the General Partner of the Special GPiFiling they signed
APAustin PenaManaging Director of the General Partner of the Special GPiFiling they signed
BFBarbara FrankOfficer of the General Partner of the GPiFiling they signed
BJBennett J. GoodmanExecutive Officer of Management CompanyiFiling they signed
BEBlackstone ETMA V (LUX) S.a r.l.The General PartneriFiling they signed
BJBrad J. MarshallExecutive Officer of the Investment AdvisoriFiling they signed
BNBrett NewmanSenior Managing Director of the General Partner of the Special GPiFiling they signed
BKBrian KimSenior Managing Director of the General Partner of the Special GPiFiling they signed
CCCampbell CongdonDIRECTORiFiling they signed
CPChris PlaccaOfficer of the General Partner of the Special GPiFiling they signed
CSChris StrianoSenior Managing Director of the General Partner of the GPiFiling they signed
CGChristopher G. StrianoSenior Managing Director of the General Partner of the Special GPiFiling they signed
CEChristopher EbanksDIRECTORiFiling they signed
We also hold 178 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Exits from the portfolio
Companies it backed that were later bought or listed10 in all
Heptares TherapeuticsBought by SoseiUndisclosedFeb 2015
TyRx PharmaBought by Medtronic$160MJan 2014
Oxford ImmunotecListed$64MNov 2013
Aerie PharmaceuticalsListedUndisclosedOct 2013
NanoString TechnologiesListed$54MJun 2013
Pearl TherapeuticsBought by AstraZeneca$1.1BJun 2013
SARcode BioscienceBought by Shire$160MMar 2013
NeomendBought by C. R. Bard$140MOct 2012
Taligen TherapeuticsBought by Alexion Pharmaceuticals$111MJan 2011
ZogenixListedUndisclosedNov 2010
An exit counts when it came after the firm's first round in the company. From historical deal records.